Cognitive impairment is a prevalent and debilitating complication in patients with chronic kidney disease (CKD). This position paper, developed by the Cognitive Decline in Nephro-Neurology: European Cooperative Target network, provides guidance on the epidemiology, risk factors, pathophysiology, diagnosis and clinical management of CKD-related cognitive impairment. Cognitive impairment is significantly more common in CKD patients compared with the general population, particularly those undergoing haemodialysis. The development of cognitive impairment is influenced by a complex interplay of factors, including uraemic neurotoxins, electrolytes and acid–base disorders, anaemia, vascular damage, metabolic disturbances and comorbidities like diabetes and hypertension. Effective screening and diagnostic strategies are essential for early identification of cognitive impairment utilizing cognitive assessment tools, neuroimaging and circulating biomarkers. The impact of various drug classes, including antiplatelet therapy, oral anticoagulants, lipid-lowering treatments and antihypertensive drugs, on cognitive function is evaluated. Management strategies encompass pharmacological and non-pharmacological interventions, with recommendations for optimizing cognitive function while managing CKD-related complications. This guidance highlights the importance of addressing cognitive impairment in CKD patients through early detection, careful medication management and tailored therapeutic strategies to improve patient outcomes.

Cognitive impairment in CKD patients: a guidance document by the CONNECT network / Bolignano, D.; Simeoni, M.; Hafez, G.; Pepin, M.; Gallo, A.; Altieri, M.; Liabeuf, S.; Giannakou, K.; De Ananya, A.; Capasso, G.; Andrade, A.; Arici, M.; Bachmann, M.; Bailey, M.; Barbieri, M.; Bobot, M.; Bruchfeld, A.; Arune-Bumblyte, I.; Rastenyte, D.; Calcutta, A.; Capolongo, G.; Carriazo, S.; Ceccarelli, M.; Covic, A. C.; Delgado, P.; Endlich, N.; Endres, M.; Esposito, F.; Farisco, M.; Faucher, Q.; Ferreira, A. C.; Figurek, A.; Fouque, D.; Franssen, C.; Fridolin, I.; Frische, S.; Garneata, L.; Gesualdo, L.; Godefroy, O.; Golenia, A.; Goumenos, D.; Jimenez, E. G.; Hoorn, E.; Silva, P. H. I.; Izhar, R.; Kelly, D.; Kesler, S.; Klimkowicz-Mrowiec, A.; Knauss, S.; Kurganaite, J.; Levassort, H.; Liabeuf, S.; Malyszko, J.; Mani, L. -Y.; Martino, G.; Massy, Z.; Mayer, C.; Mucci, A.; Mutevelic-Turkovic, A.; Nielsen, R.; Nitsch, D.; Ortiz, A.; Panagiotopoulos, V.; Karasavvidou, D.; Paolisso, G.; Pejuskovic, B.; Perna, A.; Perrottelli, A.; Pesic, V.; Pezzella, P.; Rroji, M.; Rychlik, I.; Sakkas, G.; Romeo, M. J. S.; Spasovski, G.; Starcevic, A.; Tedeschi, G.; Trevisani, F.; Unwin, R.; Vazelov, E.; Wagner, C. A.; Wagner, F.; Wanner, C.; Wiecek, A.; Xu, H.; Zacchia, M.; Zacharia, L.; Zecchino, I.; Zoccali, C.; Mattace-Raso, F.; Endlich, K. -H.; Perico, N.; Remuzzi, G.; Trepiccione, F.; Okusa, M.; Di Marzo, V.; Blankestijn, P.; Eckardt, K. -U.; Konig, M.; Gansevoort, R.; Askari, H.; Hansen, B.; Snaedal, S.; Cuiban, E.; Caporusso, E.; Lo Re, V.; Roiser, J.; Rosenberg, K.; Bisecco, A.; Denby, L.; Kulkarni, O. P.; Sharma, K.; Debnath, S.; Jaafar, A.; Capasso, A.; Mulholland, M.; Workeneh, B.; Iervolino, A.; Fraser, S.; Frey-Wagner, I.; Pastore, A.; Maciulaitis, R.; De Donato, A.; Farinha, A.. - In: CLINICAL KIDNEY JOURNAL. - ISSN 2048-8505. - 18:2(2025). [Epub ahead of print] [10.1093/ckj/sfae294]

Cognitive impairment in CKD patients: a guidance document by the CONNECT network

Martino G.
Membro del Collaboration Group
;
Trevisani F.;Capasso A.;
2025-01-01

Abstract

Cognitive impairment is a prevalent and debilitating complication in patients with chronic kidney disease (CKD). This position paper, developed by the Cognitive Decline in Nephro-Neurology: European Cooperative Target network, provides guidance on the epidemiology, risk factors, pathophysiology, diagnosis and clinical management of CKD-related cognitive impairment. Cognitive impairment is significantly more common in CKD patients compared with the general population, particularly those undergoing haemodialysis. The development of cognitive impairment is influenced by a complex interplay of factors, including uraemic neurotoxins, electrolytes and acid–base disorders, anaemia, vascular damage, metabolic disturbances and comorbidities like diabetes and hypertension. Effective screening and diagnostic strategies are essential for early identification of cognitive impairment utilizing cognitive assessment tools, neuroimaging and circulating biomarkers. The impact of various drug classes, including antiplatelet therapy, oral anticoagulants, lipid-lowering treatments and antihypertensive drugs, on cognitive function is evaluated. Management strategies encompass pharmacological and non-pharmacological interventions, with recommendations for optimizing cognitive function while managing CKD-related complications. This guidance highlights the importance of addressing cognitive impairment in CKD patients through early detection, careful medication management and tailored therapeutic strategies to improve patient outcomes.
2025
Inglese
Oxford University Press
18
2
Epub ahead of print
Esperti anonimi
Internazionale
Goal 3: Good health and well-being
CKD
cognitive impairment
neuroimaging
quality of life
uraemic neurotoxins
Cognitive impairment in CKD patients: a guidance document by the CONNECT network / Bolignano, D.; Simeoni, M.; Hafez, G.; Pepin, M.; Gallo, A.; Altieri, M.; Liabeuf, S.; Giannakou, K.; De Ananya, A.; Capasso, G.; Andrade, A.; Arici, M.; Bachmann, M.; Bailey, M.; Barbieri, M.; Bobot, M.; Bruchfeld, A.; Arune-Bumblyte, I.; Rastenyte, D.; Calcutta, A.; Capolongo, G.; Carriazo, S.; Ceccarelli, M.; Covic, A. C.; Delgado, P.; Endlich, N.; Endres, M.; Esposito, F.; Farisco, M.; Faucher, Q.; Ferreira, A. C.; Figurek, A.; Fouque, D.; Franssen, C.; Fridolin, I.; Frische, S.; Garneata, L.; Gesualdo, L.; Godefroy, O.; Golenia, A.; Goumenos, D.; Jimenez, E. G.; Hoorn, E.; Silva, P. H. I.; Izhar, R.; Kelly, D.; Kesler, S.; Klimkowicz-Mrowiec, A.; Knauss, S.; Kurganaite, J.; Levassort, H.; Liabeuf, S.; Malyszko, J.; Mani, L. -Y.; Martino, G.; Massy, Z.; Mayer, C.; Mucci, A.; Mutevelic-Turkovic, A.; Nielsen, R.; Nitsch, D.; Ortiz, A.; Panagiotopoulos, V.; Karasavvidou, D.; Paolisso, G.; Pejuskovic, B.; Perna, A.; Perrottelli, A.; Pesic, V.; Pezzella, P.; Rroji, M.; Rychlik, I.; Sakkas, G.; Romeo, M. J. S.; Spasovski, G.; Starcevic, A.; Tedeschi, G.; Trevisani, F.; Unwin, R.; Vazelov, E.; Wagner, C. A.; Wagner, F.; Wanner, C.; Wiecek, A.; Xu, H.; Zacchia, M.; Zacharia, L.; Zecchino, I.; Zoccali, C.; Mattace-Raso, F.; Endlich, K. -H.; Perico, N.; Remuzzi, G.; Trepiccione, F.; Okusa, M.; Di Marzo, V.; Blankestijn, P.; Eckardt, K. -U.; Konig, M.; Gansevoort, R.; Askari, H.; Hansen, B.; Snaedal, S.; Cuiban, E.; Caporusso, E.; Lo Re, V.; Roiser, J.; Rosenberg, K.; Bisecco, A.; Denby, L.; Kulkarni, O. P.; Sharma, K.; Debnath, S.; Jaafar, A.; Capasso, A.; Mulholland, M.; Workeneh, B.; Iervolino, A.; Fraser, S.; Frey-Wagner, I.; Pastore, A.; Maciulaitis, R.; De Donato, A.; Farinha, A.. - In: CLINICAL KIDNEY JOURNAL. - ISSN 2048-8505. - 18:2(2025). [Epub ahead of print] [10.1093/ckj/sfae294]
none
124
info:eu-repo/semantics/article
262
Bolignano, D.; Simeoni, M.; Hafez, G.; Pepin, M.; Gallo, A.; Altieri, M.; Liabeuf, S.; Giannakou, K.; De Ananya, A.; Capasso, G.; Andrade, A.; Arici, ...espandi
1 Contributo su Rivista::1.1.1 Articolo in rivista - Review
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/203077
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 20
social impact